Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Jiangsu Recbio Technology Co., Ltd. Class H ( (HK:2179) ) has provided an announcement.
Jiangsu Recbio Technology Co., Ltd. has announced the composition of its board of directors, highlighting the roles and functions of each member. This announcement provides insights into the company’s governance structure, which is crucial for its strategic direction and operational management, potentially impacting stakeholder confidence and the company’s positioning in the biotechnology sector.
The most recent analyst rating on (HK:2179) stock is a Sell with a HK$5.50 price target. To see the full list of analyst forecasts on Jiangsu Recbio Technology Co., Ltd. Class H stock, see the HK:2179 Stock Forecast page.
More about Jiangsu Recbio Technology Co., Ltd. Class H
Jiangsu Recbio Technology Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the biotechnology industry. The company focuses on the development and commercialization of innovative vaccines and related technologies.
Average Trading Volume: 39,478
Technical Sentiment Signal: Sell
Current Market Cap: HK$2.69B
See more insights into 2179 stock on TipRanks’ Stock Analysis page.